
Opinion|Videos|November 28, 2023
Strategies for Adverse Event Management in Patients With CRC Receiving Tucatinib
Toxicities with tucatinib in patients with colorectal cancer like fatigue and GI issues are generally manageable but still require close monitoring, with early optimization of diarrhea management being key to allow patients to stay on effective treatment long-term.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Gastric Cancers
2
FDA Grants Priority Review to Dostarlimab in dMMR/MSI-H Rectal Cancer
3
Lenvatinib Combo Holds Ground Against HER2 ADCs in Endometrial Cancer
4
Teclistamab Combo Earns EU Approval in Relapsed/Refractory Multiple Myeloma
5



















































